IP Library Patent Application 13789797
Patent Application
App. No. 13/789,797

LOW MELTING PROPIONIC ACID DERIVATIVE PARTICLES FOR USE IN ORAL DOSAGE FORMS

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
13/789,797
Abstract

Low melting propionic acid derivative particles that are free flowing and have significantly reduced or eliminated throat burn are disclosed. A method of manufacturing the low melting propionic acid derivative particles; dosage forms containing the low melting propionic acid derivative particles; methods of manufacturing the dosage forms; and methods of treatment using the dosage forms are also disclosed.

Claims (20)

1 . A method of manufacturing ibuprofen particles, comprising:

melting ibuprofen and a wax while mixing;

dispersing the molten ibuprofen/wax mixture in hot water;

transferring the hot ibuprofen/wax/water dispersion into another container containing cold water, wherein the dispersed droplets of ibuprofen/wax congeal and form fine/spherical particles; and

filtering and drying the fine/spherical particles.

2 . (canceled)

3 . The method of claim 1 , wherein said wax is glyceryl behenate.

4 . A method of manufacturing a dosage form, comprising:

mixing the propionic acid derivative particles of claim 1 with dosage form excipients; and

compressing the mixture into a dosage form.

5 . A propionic acid derivative particle prepared by the method of claim 1 .

6 . A dosage form prepared by the method of claim 2 .

7 . A method of treatment, comprising administering the dosage form of claim 6 .

8 . An immediate release pharmaceutical formulation comprising the propionic acid derivative particle of claim 5 .

9 . The immediate release pharmaceutical formulation of claim 8 , wherein said formulation is a chewable tablet.

10 . The immediate release pharmaceutical formulation of claim 8 , wherein said formulation is an orally disintegrating tablet.

11 . The immediate release pharmaceutical formulation of claim 8 , wherein said propionic acid derivative particles comprise from about 80 parts propionic acid derivative/about 20 parts wax to about 95 parts propionic acid derivative/about 5 parts wax.

12 . The immediate release pharmaceutical formulation of claim 9 , wherein said propionic acid derivative particles comprise about 85 parts propionic acid derivative/about 15 parts wax.

13 . The method of claim 1 , wherein said ibuprofen particles comprise from about 80 parts ibuprofen/about 20 parts wax to about 95 parts ibuprofen/about 5 parts wax.

14 . The method of claim 13 , wherein said ibuprofen particles comprise about 85 parts ibuprofen/about 15 parts wax.

Assignments (2)
MERGER AND CHANGE OF NAME Recorded Jul 1, 2015
From: MCNEIL-PPC, INC.; JOHNSON & JOHNSON CONSUMER INC.
To: JOHNSON & JOHNSON CONSUMER INC.
Reel/Frame 036042/0443 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 11, 2013
From: BAGCHI, SAUMITRA; VUPPALA, MURALI K.
To: MCNEIL-PPC, INC.
Reel/Frame 029958/0396 →